UroGen Pharma Statistics
Total Valuation
UroGen Pharma has a market cap or net worth of $1.39 billion. The enterprise value is $1.45 billion.
Important Dates
The last earnings date was Wednesday, May 6, 2026, before market open.
| Earnings Date | May 6, 2026 |
| Ex-Dividend Date | n/a |
Share Statistics
UroGen Pharma has 48.72 million shares outstanding. The number of shares has increased by 7.34% in one year.
| Current Share Class | 48.72M |
| Shares Outstanding | 48.72M |
| Shares Change (YoY) | +7.34% |
| Shares Change (QoQ) | +1.93% |
| Owned by Insiders (%) | 2.04% |
| Owned by Institutions (%) | 87.21% |
| Float | 43.18M |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | 9.91 |
| Forward PS | 4.54 |
| PB Ratio | n/a |
| P/TBV Ratio | n/a |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Financial Ratio HistoryEnterprise Valuation
| EV / Earnings | n/a |
| EV / Sales | 10.32 |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 4.69
| Current Ratio | 4.69 |
| Quick Ratio | 3.86 |
| Debt / Equity | n/a |
| Debt / EBITDA | n/a |
| Debt / FCF | n/a |
| Interest Coverage | -7.00 |
Financial Efficiency
| Return on Equity (ROE) | n/a |
| Return on Assets (ROA) | -26.98% |
| Return on Invested Capital (ROIC) | -88.56% |
| Return on Capital Employed (ROCE) | -53.29% |
| Weighted Average Cost of Capital (WACC) | 12.14% |
| Revenue Per Employee | $471,453 |
| Profits Per Employee | -$447,064 |
| Employee Count | 298 |
| Asset Turnover | 0.56 |
| Inventory Turnover | 1.00 |
Taxes
| Income Tax | -5.09M |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has increased by +290.97% in the last 52 weeks. The beta is 1.59, so UroGen Pharma's price volatility has been higher than the market average.
| Beta (5Y) | 1.59 |
| 52-Week Price Change | +290.97% |
| 50-Day Moving Average | 22.08 |
| 200-Day Moving Average | 21.04 |
| Relative Strength Index (RSI) | 61.62 |
| Average Volume (20 Days) | 1,001,850 |
Short Selling Information
The latest short interest is 7.24 million, so 14.85% of the outstanding shares have been sold short.
| Short Interest | 7.24M |
| Short Previous Month | 7.83M |
| Short % of Shares Out | 14.85% |
| Short % of Float | 16.76% |
| Short Ratio (days to cover) | 9.26 |
Income Statement
In the last 12 months, UroGen Pharma had revenue of $140.49 million and -$133.23 million in losses. Loss per share was -$2.73.
| Revenue | 140.49M |
| Gross Profit | 126.24M |
| Operating Income | -108.21M |
| Pretax Income | -138.31M |
| Net Income | -133.23M |
| EBITDA | -107.90M |
| EBIT | -108.21M |
| Loss Per Share | -$2.73 |
Full Income StatementBalance Sheet
The company has $140.27 million in cash and $197.09 million in debt, with a net cash position of -$56.82 million or -$1.17 per share.
| Cash & Cash Equivalents | 140.27M |
| Total Debt | 197.09M |
| Net Cash | -56.82M |
| Net Cash Per Share | -$1.17 |
| Equity (Book Value) | -124.25M |
| Book Value Per Share | -2.55 |
| Working Capital | 186.83M |
Full Balance SheetCash Flow
In the last 12 months, operating cash flow was -$165.74 million and capital expenditures -$299,000, giving a free cash flow of -$166.04 million.
| Operating Cash Flow | -165.74M |
| Capital Expenditures | -299,000 |
| Depreciation & Amortization | 310,000 |
| Net Borrowing | 63.17M |
| Free Cash Flow | -166.04M |
| FCF Per Share | -$3.41 |
Full Cash Flow StatementMargins
Gross margin is 89.85%, with operating and profit margins of -77.02% and -94.83%.
| Gross Margin | 89.85% |
| Operating Margin | -77.02% |
| Pretax Margin | -98.45% |
| Profit Margin | -94.83% |
| EBITDA Margin | -76.80% |
| EBIT Margin | -77.02% |
| FCF Margin | n/a |
Dividends & Yields
UroGen Pharma does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| Buyback Yield | -7.34% |
| Shareholder Yield | -7.34% |
| Earnings Yield | -9.57% |
| FCF Yield | -11.92% |
Analyst Forecast
The average price target for UroGen Pharma is $36.44, which is 27.50% higher than the current price. The consensus rating is "Strong Buy".
| Price Target | $36.44 |
| Price Target Difference | 27.50% |
| Analyst Consensus | Strong Buy |
| Analyst Count | 9 |
| Revenue Growth Forecast (5Y) | 37.65% |
| EPS Growth Forecast (5Y) | n/a |
Stock ForecastsFair Value
There are several formulas that can be used to estimate the intrinsic value of a stock.
| Lynch Fair Value | n/a |
| Lynch Upside | n/a |
| Graham Number | n/a |
| Graham Upside | n/a |
Stock Splits
This stock does not have any record of stock splits.
| Last Split Date | n/a |
| Split Type | n/a |
| Split Ratio | n/a |
Scores
UroGen Pharma has an Altman Z-Score of -4.11 and a Piotroski F-Score of 2. A Z-score under 3 suggests an increased risk of bankruptcy.
| Altman Z-Score | -4.11 |
| Piotroski F-Score | 2 |
